Designation of Lenalidomide (REVLIMID) as an orphan drug - Celgene Pty Ltd.

Administered by Department of Health, Disability and Ageing

Legislation au C2015G00178 In force Gazette

Legislation content

COMMONWEALTH OF AUSTRALIA

Department of Health
Therapeutic Goods Administration

THERAPEUTIC GOODS ACT 1989

 

DESIGNATION OF Lenalidomide (REVLIMID) AS AN ORPHAN DRUG

 

I, Dr Anthony Gill, Delegate of the Secretary for the purposes of 16J of the Therapeutic Goods Regulations 1990 (“the Regulations”), acting under subregulation 16J(2) of the Regulations, designate Lenalidomide (REVLIMID) as an orphan drug on 28 January 2015 for the treatment of patients with mantle cell lymphoma.

The dose form of Lenalidomide (REVLIMID) for this indication is capsule.

The sponsor of Lenalidomide (REVLIMID) is Celgene Pty Ltd.

 

 

(Signed by)

 

Dr Anthony Gill

Delegate of the Secretary

28 January 2015

 

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.